6-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of April 2026

Commission File Number: 001-41661

Jin Medical International Ltd.

(Exact name of registrant as specified in its charter)

No. 33 Lingxiang Road, Wujin District

Changzhou City, Jiangsu Province

People’s Republic of China

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Nasdaq Minimum Bid Price Requirement Compliance Regained and PressRelease

On April 2, 2026,  Jin Medical International Limited, an exempted company incorporated in the Cayman Islands (the “Company”) received written notice from the Nasdaq Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) that the Company had regained compliance with Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”). The closing bid price of the Company’s Class A ordinary shares had been at $1.00 per share or greater for more than ten (10) consecutive business days. In particular, the Staff determined that for the thirteen (13) consecutive business days from March 16, 2026 to April 1, 2026, the Company was able to maintain a minimum bid price of $1.00 per share.

As previously disclosed in the report on Form 6-K filed with the U.S. Securities and Exchange Commission (the “SEC”) on May 2, 2025 by the Company, the Company received a deficiency letter from the Staff of Nasdaq informing the Company that, based upon the closing bid price of the Company’s ordinary shares over the 30 consecutive business day period between March 20, 2025 and May 1, 2025, the Company was not in compliance with the Minimum Bid Price Requirement.

As previously disclosed in the Company’s annual report for the fiscal year ended September 30, 2025 on Form 20-F filed with the SEC on February 10, 2026, the Company was initially granted a 180-day compliance period through October 29, 2025, and, after not regaining compliance during that period, Nasdaq granted the Company an additional 180-day compliance period that commenced on October 31, 2025.

As previously disclosed in the report on Form 6-K filed with the SEC on March 17, 2026, the Company’s board of directors (the “Board”) was authorized pursuant to shareholders’ vote at the Company’s 2026 extraordinary general meeting on January 30, 2026, to determine, in its sole discretion, whether and when to effect any share consolidation in accordance with the shareholders’ approval. On February 3, 2026, the Board approved a combination of all of the Company’s authorized and issued Class A ordinary shares and Class B ordinary shares at a ratio of one-for-twenty (1-for-20) (the “Share Consolidation”). The Share Consolidation became effective with Nasdaq on March 16, 2026 at 09:00 a.m., Eastern Time.

After the Share Consolidation, the Company’s authorized share capital became US$50,000 divided into 45,000,000 Class A ordinary shares of a par value of US$0.001 each, and 5,000,000 Class B ordinary shares of a par value of US$0.001 each. As of the date of this current report on Form 6-K (this “Report”), the Company has 6,827,355 Class A ordinary shares issued and outstanding, and 1,000,000 Class B ordinary shares issued and outstanding.

On April 7, 2026, the Company published a press release entitled “Jin Medical International Ltd. Has Regained Compliance with Nasdaq’s Minimum Bid Price Requirement”, a copy of which is attached hereto as Exhibit 99.1.

This Report shall be deemed to be incorporated by reference into the registration statement on Form F-3 (File No. 333-288314) (the “Registration Statement”), and to be a part of the Registration Statement from the date on which this Report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

1

EXHIBIT INDEX

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

3

Exhibit 99.1

Jin Medical International Ltd. Has Regained Compliance with Nasdaq’sMinimum Bid Price Requirement

CHANGZHOU, China, April 7, 2026 /PRNewswire/ -- Jin Medical International Ltd. (NASDAQ: ZJYL) (“Jin Medical”, and together with all its subsidiaries and consolidated entities, the “Company”), a NASDAQ-listed leading provider of rehabilitation medical equipment, today announced that it has received written notification from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC confirming that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement.

The Company regained compliance after its Class A ordinary shares maintained a closing bid price of at least $1.00 per share for more than ten (10) consecutive business days.

The Company will continue to focus on its core business operations and ongoing strategic initiatives.

About Jin Medical International Ltd.

Founded in 2006 and headquartered at Changzhou, Jiangsu Province of China, Jin Medical designs, develops, manufactures and markets wheelchairs and living aids products for people with disabilities, elderlies, and for rehabilitation application. Currently, Jin Medical already operates two manufacturing plants of approximately 230,000 square feet in the aggregate in Changzhou City and Taizhou City, Jiangsu Province, China. Jin Medical is currently establishing a new facility with 430,000 square feet in Chuzhou, Anhui Province, China. Jin Medical works with more than 40 distributors in China and more than 20 international distributors. The majority of Jin Medical’s wheelchair products, with more than 30 models, are sold to distributors in Japan and China. Jin Medical continuously delivers innovative wheelchair products that are both lightweight and ergonomic. For more information, please visit: http://www.jinmed.com.

Forward-Looking Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performances, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may”, “will”, “should”, “intend”, “plan”, “strive”, “believe”, “expect”, “anticipate”, “project”, “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks, including, but not limited to, the following: the Company’s ability to achieve its goals and strategies, the Company’s future business development and plans for future business development, including its financial conditions and results of operations, product and service demand and acceptance, reputation and brand, the impact of competition and pricing, changes in technology, government regulations, import and export restrictions, fluctuations in general economic and business conditions, and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the U.S. Securities and Exchange Commission (“SEC”). For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, as well as its current reports on Form 6-K and other filings, all of which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

For more information, please contact:

ir@jinmed.com